Axogen “announces the first surgical implantations of its newest product, Avive+ Soft Tissue Matrix. Avive+ Soft Tissue Matrix is a resorbable, multi-layer, placenta-based allograft that provides temporary protection and tissue separation during the critical phase of healing for nerves. Avive+ is processed and distributed as a 361 tissue product in accordance with U.S. Food and Drug Administration Good Tissue Practices under 21 CFR part 1271 regulations. The nerve protection category covers a wide range of injuries and defects, including nerve compression, crush, complex traumatic injuries, and surgical exposures. The diversity of these injury types and their anatomical locations present unique challenges for both the surgeon and the patient. To optimize recovery, Axogen provides solutions to adequately address the nerve and the surrounding environment throughout the healing process.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXGN:
- Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
- New Accounting & Financial Operations Risk for AxoGen – What’s the Latest?
- AxoGen files $100M mixed securities shelf
- AxoGen Releases Updated Corporate Presentation Online
- AxoGen Unveils Q4 and Full Year 2023 Financial Results